Cytokinetics Net Income 2006-2021 | CYTK

Cytokinetics net income from 2006 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Cytokinetics Annual Net Income
(Millions of US $)
2020 $-127
2019 $-122
2018 $-106
2017 $-128
2016 $16
2015 $-38
2014 $-15
2013 $-34
2012 $-42
2011 $-51
2010 $-49
2009 $25
2008 $-56
2007 $-49
2006 $-57
2005 $-42
Cytokinetics Quarterly Net Income
(Millions of US $)
2021-06-30 $-62
2021-03-31 $-47
2020-12-31 $-44
2020-09-30 $-3
2020-06-30 $-41
2020-03-31 $-39
2019-12-31 $-31
2019-09-30 $-30
2019-06-30 $-32
2019-03-31 $-29
2018-12-31 $-26
2018-09-30 $-22
2018-06-30 $-28
2018-03-31 $-30
2017-12-31 $-40
2017-09-30 $-32
2017-06-30 $-29
2017-03-31 $-26
2016-12-31 $7
2016-09-30 $33
2016-06-30 $-12
2016-03-31 $-12
2015-12-31 $-9
2015-09-30 $-9
2015-06-30 $-11
2015-03-31 $-9
2014-12-31 $8
2014-09-30 $-6
2014-06-30 $-8
2014-03-31 $-9
2013-12-31 $7
2013-09-30 $-13
2013-06-30 $-15
2013-03-31 $-13
2012-12-31 $-11
2012-09-30 $-10
2012-06-30 $-10
2012-03-31 $-10
2011-12-31 $-12
2011-09-30 $-11
2011-06-30 $-16
2011-03-31 $-12
2010-12-31 $-12
2010-09-30 $-12
2010-06-30 $-13
2010-03-31 $-12
2009-12-31 $-13
2009-09-30 $-8
2009-06-30 $56
2009-03-31 $-11
2008-12-31 $-11
2008-09-30 $-16
2008-06-30 $-15
2008-03-31 $-14
2007-12-31 $-13
2007-09-30 $-11
2007-06-30 $-13
2007-03-31 $-12
2006-12-31 $-16
2006-09-30 $-15
2006-06-30 $-14
2006-03-31 $-12
2005-12-31 $-11
2005-09-30 $-10
2005-06-30 $-11
2005-03-31 $-11
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.081B $0.056B
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00